Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001–2017). (April 2020)

• Record Type: Journal Article
• Authors: Valent, Francesca; Bond, Milena; Cavallaro, Elena; Treppo, Elena; Rosalia Maria, Da Riol; Tullio, Annarita; Dejaco, Christian; De Vita, Salvatore; Quartuccio, Luca
• Is Part Of: Vascular medicine. Volume 25:Number 2(2020)
• Page Start: 150
• Page End: 156
• Publication Date: 2020-04
• Subjects: administrative databases -- arteritis -- costs -- giant cell -- prevalence; Blood-vessels -- Diseases -- Periodicals; Peripheral vascular diseases -- Periodicals; Vascular Diseases -- Periodicals; Vaisseaux sanguins -- Maladies -- Périodiques; Maladies vasculaires périphériques -- Périodiques; 616.13
• DOI: 10.1177/1358863X19886074
• Languages: English
• ISSNs: 1358-863X

Abstract

Giant cell arteritis (GCA) is the most common vasculitis in adults. However, comprehensive analyses of the healthcare burden are still scarce. The aim of the study is to report the healthcare burden and cost of illness of GCA in the Friuli Venezia Giulia (FVG) region of Italy, based on a data linkage analysis. To this end, a retrospective study was conducted through the integration of many administrative health databases of the FVG region as the source of information. Cases were identified from two verified, partially overlapping sources (the rare disease registry and medical exemption database). From 2001 to 2017, 208 patients with GCA were registered. The prevalence of GCA in the population aged ⩾ 45 years as of December 31, 2017 was 27.2/100, 000 inhabitants (95% CI 23.5–31.4). The mean time of observation was 4.5 ± 3.6 years. A total of 3182 visits (338 per 100 patient-years) was recorded. The most frequent specialty visits were rheumatology ( n = 610, 19.2%), followed by internal medicine ( n = 564, 17.7%). A total of 287 hospitalizations (30 per 100 patient-years) were reported. A total of 13, 043 prescriptions (1386 per 100 patient-years) were registered. More than half of the patients were prescribed an immunosuppressive agent. The overall estimated direct healthcare cost was €2, 234, 070, corresponding to €2374 per patient-year. Overall, GCA is a rare disease which implies a high healthcare cost.